Post-earnings recap
Reported
Thu, Dec 20, 2012
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Arrowhead Pharmaceuticals reported a loss of $0.43 per share, which did not meet any consensus expectations. The stock fell by nearly 5% following the earnings release, reflecting investor concerns about the lack of revenue details and future guidance. The company's focus remains on R&D, but the absence of specific forecasts may lead to uncertainty among investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.43 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook without providing specific future guidance. They emphasized their commitment to R&D.
Management did not provide specific guidance for future quarters.
The company is focused on ongoing research and development efforts.